Robert W. Baird Forecasts Strong Price Appreciation for Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences (NYSE:EW) had its price target hoisted by Robert W. Baird from $85.00 to $87.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical research company’s stock. Robert W. Baird’s price objective points to a potential upside of 3.32% from the stock’s current price.

Other research analysts also recently issued reports about the stock. Mizuho set a $95.00 target price on shares of Edwards Lifesciences and gave the company an “outperform” rating in a research report on Monday, April 13th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Truist Financial set a $89.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Wednesday, February 11th. Evercore restated an “outperform” rating and set a $94.00 target price on shares of Edwards Lifesciences in a research report on Monday, January 5th. Finally, Piper Sandler restated an “overweight” rating and set a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average target price of $95.39.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $84.20 on Friday. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 1 year low of $72.30 and a 1 year high of $87.89. The company has a market cap of $48.55 billion, a PE ratio of 46.01, a PEG ratio of 2.08 and a beta of 0.95. The company’s 50-day moving average is $81.71 and its two-hundred day moving average is $82.25.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same period in the prior year, the company posted $0.64 EPS. The company’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts anticipate that Edwards Lifesciences will post 2.96 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 22,680 shares of the stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $80.16, for a total value of $1,818,028.80. Following the sale, the vice president directly owned 21,266 shares in the company, valued at $1,704,682.56. This trade represents a 51.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $80.98, for a total transaction of $82,518.62. Following the completion of the sale, the vice president owned 33,934 shares in the company, valued at $2,747,975.32. This represents a 2.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 86,058 shares of company stock worth $7,118,636 in the last ninety days. Company insiders own 0.31% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Hedge funds have recently modified their holdings of the company. Hanson & Doremus Investment Management acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at approximately $25,000. JPL Wealth Management LLC acquired a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $25,000. MV Capital Management Inc. acquired a new stake in Edwards Lifesciences during the 4th quarter worth approximately $26,000. Kemnay Advisory Services Inc. acquired a new stake in Edwards Lifesciences during the 4th quarter worth approximately $27,000. Finally, True Wealth Design LLC raised its holdings in Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after buying an additional 259 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Q1 beat and raised FY26 outlook — Edwards reported adjusted EPS above consensus and roughly matched/beat revenue, then raised its FY26 EPS and sales guidance (EPS range $2.95–$3.05; sales growth guidance raised). This is the primary driver behind the stock rally. EW’s Q1 Earnings Beat, Revenues Match, ’26 View Up, Stock Climbs
• Positive Sentiment: Strong structural‑heart momentum and margin expansion — Management highlighted accelerating TAVR and TMTT growth, margin improvement and product momentum (including recent approvals), which supports higher longer‑term profitability expectations. Edwards Lifesciences beats quarterly estimates on robust demand for artificial heart valves
• Positive Sentiment: Capital return and buyback activity — Company disclosed a $500M accelerated share‑repurchase during the quarter, which supports EPS leverage and likely contributed to positive investor reaction. Edwards Lifesciences jumps 5.2% as Q1 results top expectations and full-year guidance rises
• Positive Sentiment: Analyst support — Some firms raised price targets/ratings (BTIG raised its target and reiterated buy), reinforcing bullish sentiment after the print. Price target / analyst notes
• Neutral Sentiment: Q2 guidance roughly in line — Q2 EPS guidance of $0.70–$0.76 sits around consensus, so the print is more notable for the FY lift than an outsized Q2 beat. Q1 earnings call highlights
• Neutral Sentiment: Mixed metric reporting from third parties — Some outlets show differing adjusted vs. GAAP EPS or alternate line‑item figures; these reconcileable reporting differences may cause short‑term noise. Q1 financial snapshot (third‑party)
• Negative Sentiment: Substantial insider selling — Public filings and aggregators show multiple insider sales (many executives selling shares) over recent months, which some investors interpret as a negative signal on near‑term insider conviction. Insider trading summary
• Negative Sentiment: Cost pressures — Cost of sales rose noticeably year‑over‑year (reported by some summaries), which could limit margin upside if the trend continues despite current operating margin gains. Cost / margin details

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.